Coverage Highlights

8.1.14 Crain’s Detroit Business explores NSI-566 next steps with ALS P.I., Dr. Eva Feldman, and reviews additional indication, Alzheimer’s disease, following promising animal research.
7.30.14 The Wall Street Journal interviews President/CEO, Richard Garr, on patient-directed social media’s impact on trials. NSI-566/ALS patients have independently chosen to blog online.
November 2013 FORBES' feature quotes President/CEO Richard Garr extensively, on the differentiation and commercialization of Neuralstem’s proprietary cell technology.
11.20.13 FOX Medical Team's Beth Galvin continues her NSI-566/ALS coverage at Emory with a patient’s perspective segment. Phase I patients, Ted Harada and John Conley, are featured.
November-December 2013 Bethesda Magazine feature provides rich insights on Neuralstem’s “potential wonder drug aimed specifically at rebuilding the hippocampus”: NSI-189.
October 2013 Practical Neurology interviews Chairman and CSO Dr. Karl Johe and P.I. Dr. Eva Feldman about the NSI-566/ALS trials in “Decreasing Progression, Increasing Function.”
8.28.13 FOX News Detroit walks with NSI-566/ALS Phase I patient Ted Harada and P.I. Dr. Eva Feldman on the eve of the Phase II trial.
5.30.13 Bioscience Technology ALS P.I. Dr. Eva Feldman and Neuralstem’s President/CEO Richard Garr in a feature that explores data from six extraordinary ALS responders – “as rare as a red wolf.”
9.13.12 MIT's Technology Review reports on CELL SCI research showing “paralyzed rats walk again after stem cell transplant” of NSI-566, suggesting hope for treatment of spinal cord injury.

Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.

News Coverage


  • UM researcher uses stem cells to fight Alzheimer’s

By Kim Kozlowski, The Detroit News, November 12, 2014

The promise of Neuralstem’s neural stem cell platform technology to treat neurodegenerative disorders, including ALS and Alzheimer’s disease, is the focus of this feature story on the clinical and pre-clinical work underway by NSI-566/ALS principal investigator, Eva L. Feldman, MD, PhD and her team at University of Michigan. “When you get something that works so beautifully (like this experiment), you can quickly see its translational potential. I am looking at a mouse but some day I could be looking at a man. As a clinician scientist, those are the moments you live for,” Dr. Feldman said, regarding her team’s study transplanting Neuralstem’s NSI-532.IGF cells in an animal model of Alzheimer’s disease, with data presented in October at The Congress of Neurological Surgeons Annual Meeting.

View Article

  • UCSD, other stem cell clinics get millions

By Bradley J. Fikes, U-T San Diego, October 23, 2014

Report on $8 million grant funding by the California Institute for Regenerative Medicine (CIRM) to three academic medical centers, including UC San Diego whose proposal is reported to support two stem cell-based clinical trials.

View Article

  • With three first-in-human trials, therapeutic stem cell science takes a bold step

By Science Daily, October 21, 2014

University of California, San Diego Health Sciences reports on the first of four patients, who was treated in late September 2014, in the commencement of Neuralstem’s Phase I NSI-566/chronic spinal cord injury (cSCI) trial. The Science Daily story reviews this first FDA-approved trial for cSCI as one of three ground-breaking stem cell efforts underway at UCSD, supported by the Sanford Stem Cell Clinical Center.

View Article

  • “After the Ice Bucket” - Neuralstem NSI-566/ALS Interview with Richard Garr

By Steve Usdin, Host, “BioCentury This Week,” October 19, 2014

Neuralstem's President and CEO, Richard Garr, sets out the company’s progress towards its goal of creating a neural stem cell therapy that will make ALS a manageable chronic disease and give patients a normal lifespan and good quality of life in this nearly six-minute TV segment, one of four on the future of ALS research produced by BioCentury in partnership with WUSA9, the CBS affiliate in Washington, D.C. Mr. Garr gives a thorough overview of NSI-566/ALS, including the neural stem cells; specially designed surgical devices used for the world’s first intraspinal injections; “rescue, nurture and integrate” treatment benefits, and Phase I final cohort three-year results from peer-reviewed, published data. NSI-566/ALS Phase II trials concluded final surgeries in July 2014.

View Segment

  • Spinal gap: Neuralstem goes into chronic injuries phase I, first ever cleared by FDA

By Randy Osborne, BioWorld Today, October 10, 2014

Neuralstem’s President and CEO, Richard Garr, is interviewed in this cover story reporting on the promise of Neuralstem’s NSI-566/chronic spinal cord injury (cSCI) Phase I trial, now underway at the University of California, San Diego School of Medicine. This trial, like Neuralstem’s ongoing NSI-566/ALS trials, represents the first FDA-approved stem cell trial for the indication. While both trials use the same cells and similar procedure, Mr. Garr explains that in addition to neurotrophic factors, in spinal cord injury patients the NSI-566 mechanism of action includes rebuilding neural circuitry for structural repair, “literally bridging the gap… trying to rebuild the circuitry in the gap so that the signal can come through, down the spinal cord.”

View Article

Privacy and Terms ©Neuralstem, Inc. 2016